What Is Sermorelin?
$53.55 · COA do lote publicado · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar peptídeo Sermorelin 10mgResposta Rapida
Sermorelin (GHRH 1-29) e um(a) sintetico(a) 29-aminoacido peptide with a peso molecular of 3,357.88 Da. It corresponds para o(a) N-terminal segment do(a) endogenous 44-aminoacido GHRH molecule e e considered the shortest fully functional fragment retaining full biological activity. [1] [2] Key Featu...
Sermorelin — Quick Facts
| Molecular formula | C149H246N44O42S |
|---|---|
| Molecular weight | 3357.9 g/mol |
| InChI key | WGWPRVFKDLAUQJ-MITYVQBRSA-N |
| PubChem CID | 16132413 |
| Storage | Liofilizado: 2–8°C refrigerado, proteja da luz. |
| Cited references | 20 |
Chemical identity from PubChem CID 16132413. For research use only.
Sermorelin (GHRH 1-29) e um(a) sintetico(a) 29-aminoacido peptide with a peso molecular of 3,357.88 Da. It corresponds para o(a) N-terminal segment do(a) endogenous 44-aminoacido GHRH molecule e e considered the shortest fully functional fragment retaining full biological activity. [1] [2]
Key Features:
- Binding Potency: Equipotent to full-length GHRH(1-40) in stimulating GH secretion
- Pulsatility: Stimulates natural pulsatile GH release (diferentemente de rhGH)
- Feedback: Regulated by somatostatin — overdose difficult
- Gene Transcription: Stimulates hGH mRNA transcricao, aumenta pituitary reserve [3]
Regulatory Status:
- FDA: Approved 1990 (diagnostic) / 1997 (pediatric GHD) as Geref. Voluntarily discontinued 2008 — NOT for tolerability/efficacy reasons. Now available compounded. [4]
- WADA: Prohibited (S2 — Peptide Hormones). [5]
Developer: EMD Serono, Inc. (formerly Serono Laboratories)
Pharmacokinetic Highlights:
- Bioavailability: ~5.1% in rats
- Half-Life: ~11–12 min
- Tmax: 5–20 min
- Clearance: 2.4–2.8 L/min
“Clinical Studies 🏛️ Sermorelin e o(a) classic GHRH fragment — formerly FDA-registered, with a robust tolerability record spanning pediatric, geriatric, and diagnostic applications.”
Referencias
- Chang Y, Huang R, Zhai Y, et al. Ann Transl Med, 9(5), 406, 2021.
- Prakash A, Goa KL. BioDrugs, 12(2), 139-157, 1999.
- Walker RF. Clin Interv Aging, 1(4), 307-308, 2006.
- Food and Drug Administration. Fed Register, 78(42), 14095-14096, 2013.
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Transl Androl Urol, 9(Suppl 2), S149-S159, 2020.
- Grossman AB, Savage MO, Lytras N, Besser GM. Clin Endocrinol (Oxf), 21(3), 321-330, 1984.
- Corpas E, Harman SM, Piñeyro MA, et al. J Clin Endocrinol Metab, 75(2), 530-535, 1992.
- Heiman ML, Nekola MV, Murphy WA, Lance VA, Coy DH. An extremely sensitive in vitro model for elucidating structure-activity relationships of hormonio do crescimento-releasing factor analogs. Endocrinology, 116(1), 410-415, 1985.
- Gelander L, Lindstedt G, Selstam G, et al. Horm Res, 31(5-6), 213-220, 1989.
- Khorram O, Laughlin GA, Yen SS. J Clin Endocrinol Metab, 82(5), 1472-1479, 1997.
- Khorram O, Yeung M, Vu L, Yen SS. J Clin Endocrinol Metab, 82(11), 3590-3596, 1997.
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Metabolism, 46(1), 89-96, 1997.
- Vitiello MV, Schwartz RS, Moe KE, Mazzoni G, Merriam GR. Dialogues Clin Neurosci, 3(3), 229-236, 2001.
- Sigalos JT, Pastuszak AW, Allison A, et al. Am J Mens Health, 11(6), 1752-1757, 2017.
- Schally AV, Wang H, He J, et al. PNAS, 115(47), 12028-12033, 2018.
- Jaszberenyi M, Rick FG, Popovics P, et al. Potentiation of cytotoxic chemotherapy by hormonio do crescimento-releasing hormone agonists. PNAS, 111(2), 781-786, 2014.
- Soule SG, King JA, Millar RP. J Clin Endocrinol Metab, 79(4), 1208-1211, 1994.
- Merriam GR, Buchner DM, Prinz PN, Schwartz RS, Vitiello MV. Potential applications of GH secretagogs no(a) evaluation and investigation do(a) age-related decline in GH secretion. Endocrine, 7(1), 49-52, 1997.
- Walker RF, Yang SW, Bercu BB. Robust Growth Hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci, 49(20), 1499-1504, 1991.
- Rafferty B, Coy DH, Poole S. Pharmacokinetic evaluation of superactive analogues of hormonio do crescimento-releasing factor (1-29)-amide. Peptides, 9(1), 207-209, 1988.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar peptídeo Sermorelin 10mg→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.